Eli Lilly & Co. is paying $350 million upfront to collaborate with Chinese biotech Innovent Biologics Inc. in developing new ...
SHANGHAI, Feb 9 (Reuters) - China's Innovent Biologics has struck a new deal with Eli Lilly to develop immunology and oncology drugs, under which the U.S. drugmaker will pay $350 million upfront and ...
Many breast cancer drugs block estrogen receptors inside cancer cells. Blocking the receptors early in disease progression staves off metastasis. But most patients with advanced disease eventually ...
DS-9606 was supposed to be the first antibody-drug conjugate in Daiichi Sankyo’s line of anti-cancer assets to use a modified ...
Shares of Prelude Therapeutics rose after the company said it has received Food and Drug Administration approval to proceed with a Phase 1 study for blood-cancer treatment. Shares were up 9.4% at ...
A growing body of research has examined the IRA’s implications for pharmaceutical innovation. Much of this literature has focused on the potential impact on the number of new drug launches, 5, 6 but ...
CAMBRIDGE, England--(BUSINESS WIRE)--Crescendo Biologics Ltd (Crescendo), the developer of novel, targeted, T cell enhancing therapeutics, and Cancer Research UK, the world’s largest independent ...
The field of cancer research has increasingly focused on the metabolic underpinnings of tumorigenesis, recognizing how the reprogramming of cellular energy ...
Researchers at Nano Life Science Institute (WPI-NanoLSI) and the Cancer Research Institute at Kanazawa University have ...
Experimental drugs for renal and other genitourinary cancers are more likely to be approved when pharmaceutical companies collaborate on the research, according to a study in JCO Oncology Practice.
Advances in cancer research have led to an increasing number and variety of cancer therapies in the development pipeline, but there are concerns that traditional processes for drug development, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results